Rational control of arterial pressure during labor in women with arterial hypertension by Humenna, Iryna Yevhenivna et al.
206
ORIGINAL PAPER /  OBSTE TRICS
Ginekologia Polska
2019, vol. 90, no. 4, 206–211
Copyright © 2019 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.2019.0037
Corresponding author:
Iryna Ye (Yevhenivna) Humenna
Department of Obstetrics and Gynecology № 2 of the Ternopil State Medical University, m.Voli, 1, Ternopil, 46001 Ternopil, Ukraine
e-mail: 22_leonora@ukr.net
Rational control of arterial pressure during labor  
in women with arterial hypertension
Iryna Yevhenivna Humenna, Svitlana Nikolayivna Heryak, Victoryya Yuriyivna Dobryanska
Department of Obstetrics and Gynecology № 2 of the Ternopil State Medical University, Ternopil, Ukraine
ABSTRACT
Objectives: Were to identify the advantages and disadvantages of different protocols of antihypertensive therapy in 
women with arterial hypertension during the process of labour and their effects on the labour progressing and perinatal 
complications.
Material and methods: 228 women who had childbirth in 2013–2018 in the Ternopil perinatal centre “Mother and Child” 
were surveyed. The study included full-term singleton pregnancies in cephalic presentation. According to the treatment 
program, women were divided into 4 groups: Group 1: 58 pregnant women who neglected treatment or had insufficient 
compliance; Group 2: 57 pregnant women who used methyldopa and classic beta-blockers during pregnancy and labor; 
Group 3: 57 pregnant women who received high selective beta-blocker with vasodilating properties nebivolol in addition 
to methyldopa; Group 4: 56 healthy pregnant women with normal blood pressure and without other somatic pathology.
Results: Hypertension and inadequate hemodynamic control can become risk factors for higher incidence of low birth 
weight, prolonged or discoordinated labour, excessive blood loss during and after delivery. The program of treating hyper-
tension in pregnant women with nebivolol hydrochloride provides sufficient control of blood pressure and helps to avoid 
blood pressure spikes or an excessive increase of systolic and diastolic blood pressure and heart rate during childbirth, 
which could endanger the mother’s health. 
Conclusions: The treatment with nebivolol hydrochloride for women with chronic arterial hypertension during pregnancy 
and delivery allows to normalize the progress and duration of labour, decrease the incidence of low birth weight and the 
percentage of excessive blood loss during labour.
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INTRODUCTION
The hemodynamics of a pregnant woman undergoes 
a significant burden during pregnancy, culminating in child-
birth [1, 2]. In women with the uncompromised cardiova-
scular system, heart rate, systolic blood pressure and cardiac 
output increase significantly (by 35–45%) due to the eleva-
ted circulating blood volume during delivery and directly 
in the postpartum stage [3, 4]. With the healthy course of 
pregnancy and childbirth, these changes are accompanied 
by decreased peripheral vascular resistance, which makes 
it easier for the maternal cardiovascular system to adapt to 
complex physiological requirements and hemodynamic 
conditions [5, 6].
It should be noted that for women with preexisting 
arterial hypertension before pregnancy their cardiovascular 
system has already been functioning in conditions of exces-
sive hemodynamic demands to the heart muscle and blood 
vessels; and pregnancy /labour/ postpartum stage causes 
an additional significant load to the heart and blood vessels, 
so childbirth for women with arterial hypertension is an ex-
tremely dangerous process [7]. In this regard, a significant 
amount of research is devoted to controlling blood pressure 
during pregnancy, as well as the identification of the bene-
fits and disadvantages of certain treatment programs in pre-
gnancy [8, 9], and a smaller amount of research is devoted to 
the actual course of arterial hypertension during childbirth. 
The work of Eva Martin, (2016) [10], on the treatment of 
the rise of arterial pressure during childbirth, draws atten-
tion. According to this report, women who had high blood 
pressure during childbirth (more than 2.500 birth histories 
were analyzed) had a 4-fold higher number of disabling 
complications, namely the thrombotic and hemorrhagic 
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complications (cerebral stroke and myocardial infarction), 
angina attacks, convulsive states, sepsis, blood transfusion. 
This study also compared methods of emergency care for 
sudden high blood pressure spikes during labour and the 
correlation of each method with the number of debilitat-
ing complications. However, the aforementioned study did 
not aim to consider methods for controlling blood pressure 
during pregnancy and the effect of controlling arterial hy-
pertension during pregnancy on the course of labour, but 
only the urgent „spikes” and severe range hypertension 
during labor and its urgent care, that allows to continue the 
scientific research in this direction.
Objectives 
Were to identify the advantages and disadvantages of 
different protocols of antihypertensive therapy in women 
with arterial hypertension during the process of labour 
and their effects on the labour progressing and perinatal 
complications.
MATERIAL AND METHODS
Participants
During 2013–2018, 228 women were surveyed in Ter-
nopil regional perinatal centre „Mother and Child”, and their 
charts were analyzed. Arterial hypertension was verified in 
172 women, 56 women were healthy and formed a control 
group. The study included labouring women on 40 ± 2 we-
eks of gestation.
The criteria for inclusion of pregnant women in the 
trial were: 1) singleton pregnancy; 2) the onset of labour 
in the anterior occipital presentation; 3) the presence of 
the arterial hypertension of the I-II stage or episodes of 
hypertension in the history; 4) the possibility of observing 
all the patients from the 12th week up to the childbirth and 
within 90 days of the postpartum stage; 5) the absence of 
previous myocardial infarction or cerebral haemorrhage; 
6) the absence of clinical manifestations of preeclampsia 
at the start of observation; The exclusion criteria were: 
1) severe concomitant somatic pathology (diabetes mellitus, 
hypo/hyperthyroidism, cardiac failure, renal failure, severe 
anaemia etc.) or severe obesity; 2) infectious pathology 
(pneumonia, pyelonephritis); 3) traumatic injuries during 
pregnancy.
According to the treatment protocol during pregnan-
cy and childbirth, the laboring women were divided into 
4 groups: the 1st group — 58 pregnants who neglected 
the treatment of arterial hypertension before pregnancy 
and had insufficient compliance during pregnancy; the 2nd 
group — 57 pregnants with arterial hypertension, who used 
methyldopa and classic beta-blockers, (atenolol, metoprolol, 
bisoprolol) during pregnancy; the 3rd group — 57 pregnants 
who received high selective beta-blocker with vasodilating 
effect nebivolol hydrochloride (5–10 mg orally per day) in 
addition to methyldopa; the 4th group — 56 healthy pre-
gnants without hypertension or other somatic pathology.
Interventions 
Arterial pressure was monitored using the Holter system 
for surveyed women from the beginning of labour and wi-
thin 48 hours after childbirth to analyze the effectiveness 
of different therapy protocols. Measurement of the basic 
parameters of central hemodynamics and respiration rate 
was performed at the beginning of the 1st stage of labour; 
at the start of an active phase of labour (cervical dilatation 
more than 3 cm), in the 2nd stage of labour, in the 3rd stage 
of labour and 2 hours after delivery.
Statistical analysis
Quantitative variables were expressed as mean ± SD and 
categorical variables as number and percentage.
Ethical approval
Informed consent was obtained from the all pregnant 
women after notified verbally and in writing about the 
detailed plan, assumptions and scope of the study. The 
research project was approved by the Ethics Committee of 
the Ternopil State Medical University, Ternopil, 2014. 
RESULTS
In the 1st group, the highest spikes of systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) that exceeded 
the rates in pregnancy by 20–45% were present. At the onset 
of labour, there was a sustained high blood pressure with 
a maximum peak of 168.2 ± 5.82 mm Hg in the 2nd stage 
and a moderate decrease to 140.2 ± 1.26 mm Hg in the 3rd 
stage of labour (Tab. 1). 
Patients of the 2nd group, who received methyldopa and 
beta-blockers without vasodilating properties had insignifi-
cant spikes of systolic pressure at the onset of labour, SBP 
differed from the weekly values by over 12%, and rigidity 
of DBP was observed. 
Comparing heart rate in the Group 2 and Group 4, the 
increase in heart rate of Group 2 women does not corre-
spond to the rate of increase in healthy women, and ranges 
by only 4 beats per minute, that is 20% less than in healthy 
pregnant women. The insufficient compensatory increase of 
heart rate was accompanied by shortness of breath while in 
healthy childbirths respiratory rate grew smoothly, changing 
to slow deep breathes during pushes. 
In women belonging to Group 3, the SBP and DBP did 
not exceed the values determined as normal blood pressure. 
The increase in heart rate and respiratory rate were close to 
the same in the control healthy group. These parameters 
indicate that adequate control of blood pressure during 
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childbirth was achieved. That let to avoid sharp spikes of 
SBP, DBP, and heart rate, which would pose a health hazard 
to the mother and the newborn. Patients in this group did 
not suffer from shortness of breath. This indicated the pro-
vision of adequate reactivity of the circulatory system in 
these women.
The important indicators in obstetrics are the amount 
of blood loss, the weight of the newborn and his/her Ap-
gar scale scoring and can be relevant to the protocol of 
antihypertensive therapy that was used for hypertensive 
pregnant (Tab. 2).
The highest blood loss was observed in women who ne-
glected the treatment of arterial hypertension. In patients of 
Group 2, the level of blood loss did not significantly exceed 
the same parameters of the patients belonging to Group 3, 
and slightly exceeded the blood loss of healthy women. 
The blood loss in Group 3 was close to average blood loss 
of healthy childbirth in our study.
Newborn babies from mothers of the Group 1 and 
Group 2 had lower values of Apgar score than in newborns 
from mothers of Group 3 which was close to the results 
of newborns in the control group. The lowest rates were 
in newborns from mothers of Group 2 but did not differ 
significantly from the Group 1. 
The importance of hemodynamic control in women with 
arterial hypertension during labour could be shown com-
paring the incidence of prolonged labour and the number 
of common complications in each group (Tab. 3). 
Table 1. Parameters of arterial pressure and heart rate in the labouring women (M ± m)
Groups (п = 88) Labour progress SBP, mm Hg DBP, mm Hg Heart rate, per min. Respiratory rate, per min.
1 group Onset of labor 136.2 ± 1.78∗ 108.8 ± 1.08∗ 92.0 ± 1.88 18.8 ± 1.15
First stage 139.2 ± 3.11∗ 110.4 ± 4.24∗ 92.0 ± 5.55 21.0 ± 1.22
 Second stage 168.2 ± 5.82∗ 111.2 ± 1.43∗ 111.0 ± 6.50∗ 22.4 ± 1.33
Third stage 140.2 ± 1.26∗ 108.8 ± 0.92 99.0 ± 4.28 21.2 ± 1.12
2 h. after delivery 138.2 ± 4.98∗ 92.6 ± 1.12∗ 80.0 ± 4.66∗ 20.1 ± 1.25
2 group Onset of labor 138.2 ± 3.15∗ 102.8 ± 1.08 77.0 ± 6.81 19.8 ± 1.32
First stage 143.3 ± 4.34∗ 102.1 ± 1.24∗ 79.0 ± 4.94 21.8 ± 1.53
 Second stage 149.8 ± 5.39∗ 103.4 ± 2.59∗ 81.0 ± 4.81 25.3 ± 1.22
Third stage 140.2 ± 1.26∗ 102.8 ± 2.92 80.0 ± 2.88 22.5 ± 0.68
2 h. after delivery 138.2 ± 2.98∗ 90.6 ± 1.12∗ 74.0 ± 1.56∗ 20.5 ± 0.88
3 group Onset of labor 125.2 ± 2.15 88.6 ± 1.08 80.0 ± 1.81 18.6 ± 1.30
First stage 125.3 ± 2.34 90.6 ± 2.24 81.0 ± 3.94 19.0 ± 1.88
 Second stage 142.8 ± 2.52 94.8 ± 0.59 87.0 ± 4.41 22.0 ± 1.56
Third stage 130.2 ± 2.26 86.8 ± 3.92 80.8 ± 1.88 21.8 ± 1.34
2 h. after delivery 128.2 ± 2.98 85.5 ± 2.12∗ 76.0 ± 2.56∗ 20.5 ± 1.08
4 group Onset of labor 118.2 ± 2.15 78.8 ± 1.08 87.0 ± 2.81 18.6 ± 1.06
First stage 113.3 ± 4.34 78.1 ± 1.24 91.0 ± 3.94 18.8 ± 1.06
 Second stage 126.6 ± 2.39 82.9 ± 0.59 99.0 ± 5.81 20.8 ± 1.42
Third stage 121.2 ± 2.26 81.2 ± 0.92 89.0 ± 5.88 18.8 ± 1.34
2 h. after delivery 111.2 ± 3.98 76.6 ± 1.12 80.0 ± 2.56 19.8 ± 1.12
Note: ∗ — the values of the indices are significantly different from the control data (p < 0.05)
Table 2. Some parameters the childbirth outcome in women with arterial hypertension, depending on the treatment protocol, and in the control 
group (M ± m)
Indicator Group 1 (58 women) Group 2 (57 women) Group 3 (57 women) Group 4 (56 women) 
Blood loss, mL 331.1 ±11.2∗ 288.6 ± 23.1∗ 245.4 ± 14.6 234.5 ± 10,7
Birthweight 3118.9 ± 32.9∗ 3002.2 ± 31.2∗ 3224.6 ± 3.03 3298.5 ± 32.9
Apgar scoring 1 min 7.4 ± 1.2∗ 7.3 ± 1.2∗ 7.9 ± 1.9 8.2 ± 1.8
Apgar scoring 5 min 8.9 ± 1.4 9.0 ± 0.9 9.6 ± 0.4 9.8 ± 0.2
Note: ∗ — the values of the indices are significantly different from the control data (p < 0.05)
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A reliably higher percentage of women who experi-
enced prolonged or discoordinated labour was detected in 
groups with chronic arterial hypertension and we attribute 
that finding being a reflection of the general, systemic pro-
blem in the body of a woman suffering from hypertension. 
In groups 1 and 2, there was a reliably higher number of 
women for whom labour induction was necessary (use of 
prostaglandins, oxytocin, amniotomy, etc.). The number of 
women required such intervention was twice lower in the 
group using nebivolol hydrochloride. In the control group, 
there were only 2 cases of prolonged labour in primipara 
and 2 cases in multipara, which is twice less than in Group 3, 
and four times less than in groups 1 or 2. 
The blood loss during labour in patients with chronic 
arterial hypertension was significantly higher. Thus, in 17 pa-
tients of Group 1 and 15 patients in Group 2, the blood loss 
in childbirth was more than 400 mL. The patients in Group 
1 and 2 who underwent a cesarean section, had hemorrha-
gic complications with a blood loss over 1000 mL. In women 
of Group 3, the incidence of bleeding over 400 mL was 
5 women (8.8 %). In the control group, 2 women (3.6 %) had 
blood loss over 400 mL, 1 of which had a cesarean section.
The number of newborns weighing less than 2500 g was 
10 (17.9%), in Group 1; 11 (19.3%) in Group 2; and 6 new-
borns (10.5%) in Group 3. While in the control group only 
2 newborns weighed less than 2500 g, (2450 g and 2490 g, 
in mothers with asthenic body structure and small height 
(both women were 158 cm in height).
Macrosomia occurred uniformly in all groups from 7.1 to 
10.7%, and it was most likely genetically determined and 
did not reliably affect the general characteristics of the 
studied parameters.
DISCUSSION
Nowadays, big trials provided enough evidence that 
hypertension is associated with increased maternal (such 
as stroke, myocardial infarction, heart or renal failure) and 
fetal risks, increased perinatal morbidity and mortality and 
placental abruption rate, and that treatment of chronic hy-
pertension may prevent progression to severe hypertension 
[11–14]. In addition, the encephalopathy syndrome, defined 
as the presence of neurological symptoms coupled with the 
radiologic findings of vasogenic cerebral oedema, seems to 
occur at lower peak SBP in pregnant compared to non-pre-
gnant patients with hypertensive encephalopathy [14–19]. 
There are also data showing that the presence of hy-
pertension itself results in lower birth weights, regardless 
of the use of medication, because arterial hypertension 
impairs placentation even at the early stages of gestation 
compromising normal blood supply on later terms [20–22] . 
The levels of blood pressure when therapy should be 
provided is still controversial. An important task for medical 
provider is to help the pregnant woman and her fetus to 
hold out until and during the childbirth, to ensure an ade-
quate reserve of compensatory mechanisms and to prevent 
maternal cardiovascular or other complications. 
The choice of antihypertensive medications has been 
limited to those that have proven to be relatively safe and 
have acceptable side-effect profiles. Methyldopa and hy-
dralazine, respectively, are recommended as initial oral or 
intravenous therapy [23–25]. Methyldopa has a record of 
safety in pregnancy, the disadvantage is slow and low effica-
cy of the antihypertensive effect. For the second-line drugs 
are calcium antagonists and β-blockers [26, 27]. Calcium 
antagonists can cause a sudden or excessive decrease of blo-
od pressure impairing uteroplacental-fetal perfusion, and 
therefore, fetal distress, or side effects for mother (headache, 
skin flushing, swelling of legs, tachycardia, dizziness). The 
main side effects of β-blockers for mother are bradycardia, 
bronchospasm, dyspeptic symptoms, skin-allergic reac-
tions, violations of contractile activity of the uterus and 
intrauterine growth retardation of the fetus, or bradycardia, 
hypotension, hypoglycemia, respiratory depression in the 
newborn [27, 28].
Therefore, cardioselective β-blockers with vasodilating 
properties may be preferable and prevent the negative ef-
Table 3. The frequency of labour complications comparing different protocols of arterial hypertension therapy and control group
Labor special features Group 1  (58 women) [%]
Group 2  
(57 women) [%]
Group 3  
(57 women) [%]
Group 4  
(56 women) [%]
Women with 1st stage lasting over 8 hours 
(primapara) 10 17.9 10 17.5 5 8.6 2 3.6
Women with 1st stage lasting over 2 hours 
(multipara) 13 23.2 13 22.8 4 7.0 2 3.6
Women with blood loss over 400 mL 17 30.4 15 26.3 5 8.8 2 3.6
Women with blood loss over 1000 mL 2 3.6 1 1.8 0 0.0 0 0.0
Neonates with birthweight less then 2500 10 17.9 11 19.3 6 10.5 2 3.6
Macrosomia 6 10.7 6 10.5 5 8.8 4 7.1
Cesarian section 2 3.6 2 3.5 1 1.8 1 1.8
210
Ginekologia Polska 2019, vol. 90, no. 4
www. journals.viamedica.pl/ginekologia_polska
fects of non-selective β-blockers [27, 29]. In particular, ne-
bivolol lowers the heart rate less than other cardioselective 
β-blockers is recognized as an advantage, in combination 
with peripheral vasodilatation, it has a better effect on central 
arterial pressure. The main mechanism of nebivolol action is 
associated with the stimulation of the NO synthesis and bra-
dykinin, which provide peripheral arteriolar vasodilation [30] 
and restoration of vascular endothelial function. Nebivolol 
also did not show central sympathomimetic action, that is 
why it does not affect central aortal pressure, normalization 
of which is extremely important for the adequate provision 
of uteroplacental-fetal circulation [27, 29, 30]. 
The results obtained on nebivolol hydrochloride proved 
to reduce the incidence of typical obstetric complications 
by almost twice compared with patients who generally 
denied treatment or were treated with β-blockers without 
vasodilating properties, but the frequency of both hemo-
dynamic and obstetric problems still remained 1.5–2 times 
higher than in healthy pregnant women with normal blood 
pressure. These results allow to achieve the better obstetric 
and perinatal outcomes, but are not an absolute solution of 
the problem, since the problem of arterial hypertension and 
its manifestations during pregnancy affect the extremely 
complex mechanisms of hemodynamics, hormonal balance, 
immunity, genetics and even the psychological aspects of 
the health of the pregnant woman.
CONCLUSIONS
Hypertension and insufficient hemodynamic control 
are the risk factors for prolonged or discoordinated labour 
and excessive blood loss during and after childbirth, and 
a higher incidence of low birth weight infants. 
The pregnants who neglected treatment or have insuffi-
cient compliance, have the highest risk of somatic complica-
tions, their hemodynamic indices (SBP and DBP, heart rate) 
during childbirth exceeded significantly than required for 
compensatory mechanisms of the body for childbirth. They 
also had the highest rates of blood loss during childbirth as 
well as their newborns had lower average birth weight and 
lower Apgar score at the 1 minute compared with healthy 
mothers and those who received treatment with nebivolol 
hydrochloride.
The pregnants who were given methyldopa and classic 
beta blockers had reliable control of hemodynamics during 
childbirth, but mechanisms of responses showed decom-
pensation and were manifested in dyspnea, as well as their 
newborns had lower average birth weight and lower Apgar 
score at the 1 minute compared with healthy mothers and 
those who received treatment with nebivolol hydrochloride. 
Pregnants who used nebivolol hydrochloride confirmed 
adequate control of the central hemodynamics: SBP, DBP, 
heart, and respiratory rate did not exceed the referent valu-
es. The duration of labour and blood loss did not significantly 
exceed comparing to healthy women, and the assessment 
of newborns by the Apgar scale was close to the assessment 
of infants born from healthy mothers.
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